which is the first immunochemical method proposed for the detection of 'AKA', should be validated on larger series of patients but can already be considered as a very powerful test for the serological diagnosis of RA.
(Ann Rheum Dis 1994; 53: [735] [736] [737] [738] [739] [740] [741] [742] A wide variety of circulating autoantibodies are found in most patients with rheumatoid arthritis (RA). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Among these antibodies, the rheumatoid factor (RF), mainly of the M isotype, is considered to be characteristic of the disease. Thus it is currently used in the diagnosis of RA' "' and constitutes one of the classification criteria proposed by the American Rheumatism Association."6 However, based on the methods commonly used for its detection (latex and Waaler-Rose tests) and the threshold titres generally considered as significant, this autoantibody shows a low diagnostic specificity. It is found in patients with various other autoimmune rheumatic diseases, and even in a noticeable proportion of normal healthy subjects. '7 Since the first study by Young et al, '8 numerous authors9-32 have described in RA, serum IgG antibodies labelling the stratum comeum of rat oesophagus epithelium. It is now largely accepted that their presence constitutes the most specific serological criterion for the diagnosis of RA.'9 21 In the absence of any biochemical characterisation of the antigen(s) they recognised, these antibodies were called 'antikeratin antibodies' ('AKA'), probably because the cytokeratins constitute the major protein component of the stratum comeum of cornified epithelia. Previous results,29 obtained by the simultaneous IIF assay of a series of RA serum samples both on rat oesophagus epithelium and on human epidermis, suggested that 'AKA' are genuine autoantibodies since the antigen(s) they recognise is also present in the stratum comeum of human epidermis. Using an enzyme-linked immunosorbent assay (ELISA) specific for the detection of antibodies to human epidermal cytokeratins,36 we also showed that 'AKA' differ from the natural autoantibodies to these proteins.32 Moreover, the antigenic proteins from rat oesophagus epithelium and from human epidermis recognised by the 'AKA' were recently biochemically characterised in our laboratory. The rat oesophagus antigens correspond to three non-cytokeratin late differentiation proteins which had not been previously described and could be related to 10 mmol/l Tris-HCl, 500 mmol/ NaCl, pH 7 5, the colour reaction was developed by incubation with peroxidase substrates: 0 5 mg/ ml 4-chloro-1-naphthol (Bio-Rad), 0-025% (v/v) hydrogen peroxide, 17% methanol (v/v) in the latter Tris buffer. A negative control, using working buffer without serum, was always included.
Similar to the fluorescence intensity in IIF, the intensity of labelling of each immunoreactive band was estimated by two readers uninformed of the clinical context, according to a semiquantitative scale ranging from 0 to 4, and the results of the two readers were summed. In previous experiments, such semiquantitative data were found to be strongly correlated (r = 097) to quantitative estimations obtained with the use of a densitometer (model GS-670, Bio-Rad laboratories). To correct inter-assay variations, which arose mainly from the use of series of antigencoated nitrocellulose membranes, a pool of highly positive RA serum samples was diluted to 1:400 and to 1:3200 and tested with two strips of each membrane. For each membrane, the estimated values of the labelling intensities of the A, B and C proteins obtained with the two dilutions of the pool were summed. A correction coefficient was then computed for each membrane according to the formula: average of the sums obtained with the whole series of membranes/sum obtained for the given membrane. The correction coefficients ranged between 0-72 and 1-63. All the semiquantitative evaluations performed after assay of the serum samples on the other strips of each membrane were then corrected by the related coefficient. All the serum samples were tested in duplicate on strips from different membranes and the results presented here correspond to the average values of the two assays, which we call titre-like values.
The semiquantitative evaluation of the reactivity to each of the three bands having been performed using three independent scales, the titre-like values of the antibodies to each protein could not be compared in a given serum sample, but allowed the reactivity to a given protein to be compared between the various serum samples.
RHEUMATOID FACTOR
IgM-RF was determined by ELISA using the AutostatTM IgM Rheumatoid Factor kit, as described by Cogent Diagnostics Ltd (Edinburgh, United Kingdom).
RF was absorbed from sera on IgG-agarose prepared using highly purified human IgGs (Sigma Chemical Co, St Louis, MO). Each RA serum (100-150 ,ul) was diluted in three volumes of PBS and run three times through a 200 pd packed-resin column. The exact volume of the pooled flow-through fractions (600-800 [ul) was measured to correct the dilution factor in the subsequent immunoblotting experiments. IgM-RF was determined before and after absorption, as described above.
To affinity-purify RF, the resin from different columns was packed. After extensive washing, RF was eluted with 0-2 mol/l glycine-HCI, pH [2] [3] [4] [5] and immediately neutralised by the addition of 0 05 volumes of 2 mol/l Tris base.
To test the effect of RF (about 400 IU/ml) on the 'AKA' reactivity, 50 RI of various sera were diluted to 1:10 in 200 [LI of the affinitypurified RF solution (or neutralised elution buffer) and 250 RI of working buffer, and analysed by immunoblotting as described above.
STATISTICAL ANALYSES Median differences were tested with the MannWhitney U-test, correlations were sought by computing Spearman's rank correlation coefficient and the x2 test was used to compare percentages. The diagnostic value of 'AKA' detection by immunoblotting was assessed by computing the diagnostic sensitivity = *The serum samples were grouped according to the protein(s) they labelled, whatever the intensity of labelling. The labelling of each protein was noted with an 'X' in the relevant column and was taken as positive when it had been considered to be present by each of the two readers in each of the two assays.
Among the eight different patterns of labelling that could theoretically be defined combining the presence or absence of labelling of each band, six were actually observed, among which three were produced by 97-3% of the serum samples, that is, the labelling of A + B + C, of A + B or of B alone. The whole analysis is presented in the table. A large majority (81-8%) of the RA serum samples simultaneously recognised the three proteins. All but one of the RA serum samples that presented significant IIF titre-like values of 'AKA' showed this pattern. In contrast, the three proteins were simultaneously labelled by only five of the 100 control serum samples which mainly labelled both A and B proteins (6 1%) or B protein alone (29%).
After semiquantitative evaluation of their reactivity to the three proteins, the RA serum samples ranged all along the titre-like value scale, whatever the considered protein, with median titre-like values of 4-22, 5 05 and 4-80, for the A, B and C proteins, respectively (fig 3) . On the other hand, the titre-like values of antibodies in the control serum samples were restricted to the lower part of the scale, since the maximum titre-like values were 4 74, 5-76 and 2-32 and the median values were 0-51, 1 16 and 0 00, for the A, B and C proteins, respectively.
To demonstrate that the differences in the In the control serum samples, the titre-like values for antibodies labelling the B protein alone (median = 0 56) were significantly lower than the titre-like values for antibodies labelling B protein in the A + B pattern subgroup (median titre-like value 1-50) (p < 0.0001). The very strong correlation we found between the titres of antibodies labelling the A protein and those of the antibodies labelling the B protein being taken into account (see below), it was seen that the shift from the pattern B alone to the pattern A+ B only depended on the increase of the antibody titre.
Diagnostic indexes
The diagnostic sensitivity and specificity were computed from the distribution of the RA and the control serum samples at each step of the semiquantitative scale separately for each protein. The resulting curves (fig 3) showed that the detection of antibodies to the A and B proteins presented comparable sensitivity and specificity for the diagnosis of RA. However, at a threshold corresponding to the first step of the semiquantitative scale (0 25) while the specificities were only 32% (2280/o-41/2%) and 4% (0-1/o-7-9%) for the detection of antibodies to the A and B proteins, respectively. At a chosen specificity of 99%, the diagnostic sensitivities of the detection of antibodies to the A and to the B proteins were 50% (39 60/6-604%) and 43T2 (32.80/o-53.6%), respectively. These sensitivities did not significantly differ from .-ach other or from the diagnostic sensitivity of the detection of 'AKA' by IIF which was 42% (31 60/o-52.4%). In contrast, the diagnostic sensitivity of the detection of antibodies to the C protein was 70.5% (60.90/o-80d1%) and was found to be significantly higher than all the above cited sensitivities (p < 001). Moreover, the latter diagnostic sensitivity was also found to be significantly higher than the diagnostic sensitivity of the detection of IgM-RF by ELISA that was 54*5% (43.90/-65-1/), at a threshold of 191 IU/ml chosen to get the same specificity of 99% (p = 0 04).
STATISTICAL AND IMMUNOCHEMICAL RELATIONSHIPS BETWEEN THE VARIOUS ANTIBODIES STUDIED
The relationships between the IgM-RF determined by ELISA, the titres of antibodies to the stratum corneum of rat oesophagus epithelium detected by IIF and those of the antibodies to the A, B and C proteins detected by immunoblotting, were sought separately in the RA and in the control serum samples.
In the group of RA patients, the titres of antibodies to the A and to the B proteins, to the B and to the C proteins, and to the A and to the C proteins were found to be strictly correlated (r = 097, 0-83 and 0-79, respectively, with p < 0-0001). In the group of control patients, the antibodies to the A and to the B proteins were also found to be strongly correlated (r = 0-96, p < 0.0001) but varied independently of the antibodies to the C protein.
In the group of RA patients, the antibodies to the A, B and C proteins were found to be correlated with the titres of 'AKA' detected by IIF (r = 0 53, 0 53 and 0-56, respectively, with p < 0 0001), while, in the group of control patients, the IIF titres were found to be independent of the antibody titres to the three proteins.
In the group of RA patients, the titres of 'AKA' detected by IIF were found to be correlated with the IgM-RF detected by ELISA (r = 0-31, with p < 0 01), as generally observed. In this group, the antibodies to the A, B and C proteins were also found to be correlated with the IgM-RF (r = 0 34, 0 37 and 0-36, respectively, with p < 0 001). In the group of control patients, the IgM-RF values were found to be independent of the other detected antibodies.
In the subset of RA patients with titre-like values of antibodies to the C protein <1-75, 350/o (9/26) were RF-positive at the specificity threshold of 99%/o (-191 IU/ml). In particular, two of the latter sera did not react with the C protein at all. Similarly, in the subset of RA We further evaluated the immunological relationship between RF (all isotypes) and antibodies to the C protein, in particular an eventual cross-reaction of RF with the protein and an eventual RF-induced amplification of immunoblotting reactivity. With this aim, four serum samples with a high value of RF (>839 IU/ml) were run through columns of human IgG coupled to agarose. By this means, up to 91% and at least 37% of IgM-RF was absorbed. When the absorbed and unabsorbed serum samples were compared by immunoblotting analysis, no modification of reactivity was seen (fig 4) . In addition, RF eluted from the columns, were added in two control and one RA serum samples with low titre-like values of antibody to the C protein.
As expected if RF does not interfere with the immunoblotting assay, the low reactivities to the C protein were not modified (data not shown).
Discussion
The immunoblotting assay we present here is the first immunochemical method proposed to date for the detection of 'AKA'.
The aim of the study was to obtain a test presenting diagnostic performances equal to or better than those of the standard IIF method. This was achieved because, although all 88 RA serum samples and also 97 of the 100 control serum samples were found to be reactive to at least one of the three protein antigens, the reactivity was found to be different in terms of labelling pattern as well as in terms of titre-like values, allowing RA to be diagnosed with a high specificity. We have shown in previous IIF studies29 31 that, because of the probable presence of low titred non-disease-specific antibodies which label the stratum corneum of rat oesophagus epithelium, the presence of 'AKA' can only be asserted with sufficient specificity when their titre-like value reaches a threshold of 1-5 (95% specificity) or 2-0 (99% specificity). The immunoblotting detection of 'AKA' followed the same rule since the detection of antibodies to the A and to the B protein required the choice of a convenient threshold (4.25 and 5 50, respectively), to reach a specificity of 99% for RA. At these thresholds, the sensitivity was similar to that of IIF 'AKA' detection (near 45%). The detection of the antibodies to the C protein allowed the same specificity to be obtained at a threshold of 1-75. At this threshold, the diagnostic sensitivity of the detection of antibodies to the C protein (70/5%) was significantly higher than those of the antibodies to the A and B proteins as well as that of the detection of 'AKA' by IIF. For diagnostic purposes therefore the antibodies to the C protein could be considered alone, whatever the labelling of the other protein antigens. The mere presence of these antibodies, whatever their titre-like value, allowed 81-8% (-+/8%) of RA to be diagnosed with a specificity of 94% (±+233%).
The analysis of the labelling patterns showed that a large majority of the RA serum samples labelled the three proteins (A + B + C) simultaneously. In the RA serum samples, the titres of the antibodies that labelled the three proteins were found to be strongly correlated with each other and also correlated with the titres of 'AKA', detected by IIF. The values of the correlation coefficients favour the hypothesis that the antibodies detected on the three proteins are largely the same and that the epitopes recognised by 'AKA' on the stratum corneum of rat oesophagus epithelium are shared by the three protein antigens detected by immunoblotting.
Of the reactive control serum samples, 95% labelled either the A and B proteins or the B protein alone. The idea that the antibodies which label the A and the B protein in the control serum samples are identical, was supported by the close correlation we found between their titre-like values, the labelling of the B protein alone not being a pattern distinct from A + B, but only resulting from the low titre of the antibodies. In addition, we showed that the near-absence of labelling of the C protein by the control serum samples did not result from their lower median titre-like value with regard to the RA serum samples, but indicated the actual absence of antibodies to the C protein. As a whole, these results showed the presence, in the serum samples from patients with non-RA rheumatic diseases, of non-disease-specific antibodies recognising epitopes shared by the A and B proteins but absent from the C protein.
The existence of at least two independent antibody families distinguishable by their labelling pattern (A + B + C: specific for RA; A + B: non-disease specific) can be used as a criterion for immunoblotting interpretation. Indeed, the classification of the serum samples according to their labelling pattern allowed RA to be diagnosed with a specificity of 95% (only five false positives) and a sensitivity of 81-8% (table), these diagnostic indexes being similar to those of the detection of antibodies to the C protein at a threshold of 0-25.
The association between RF and 'AKA', detected by IIF or by the immunoblotting assay we developed, is closed. However, it seems unlikely that a cross-reaction exists between RF and 'AKA' for the following reasons: (1) Whereas RA-specific 'AKA' are exclusively IgG, RF are mainly of the M isotype. (2) It is well known that 'AKA' occur in RF-negative RA. In the same way, we also detected immunoblotting activities to the C protein in IgM-RF-negative RA. Moreover, some 'AKA'-positive serum samples have been described as completely negative for IgG-RF35. (3) Absorption of 'AKA'-positive serum samples with aggregated human IgG, to remove RF, did not abolish 'AKA' activity. 18 Similarly, absorption of the samples on agarose-coupled IgG did not modify their immunoblotting activity toward the three proteins of rat oesophagus epithelium. (4) The addition of affinity-purified RF to RA sera did not modify their immunoblotting reactivity.
Besides 'AKA', another powerful diagnosis marker antibody, the antiperinuclear factor, has been described in RA serum samples. 33 Since 'AKA' react with filaggrin in the comified cells of human epidermis38 and the antiperinuclear factor reacts with superficial cells of human buccal epithelium (two squamous epithelia), the two antibodies could possibly be related. The antigen recognised by the antiperinuclear factor needs to be purified and characterised to highlight the exact relationship between both the RA-specific antibodies.
In conclusion, the previous isolation and characterisation of the rat oesophagus epithelium antigens recognised by the so-called 'AKA', allowed us to develop an original immunoblotting assay for the diagnosis of RA. The analysis of the immunoblotting labelling patterns showed that the RA-specific antibodies recognised epitope(s) shared by the three protein antigens, while non-RA-specific antibodies found in control patients reacted with epitope(s) shared by only two of the three proteins. Even if determined on a sample of 188 patients representative of a larger sample of 528 patients, the diagnostic performances of the immunoblotting assay should be validated on larger series of patients, particularly patients with systemic lupus erythematosus, systemic sclerosis and other connective tissue diseases, but also other types of chronic arthritides. However the performances already seem to be clearly better than those of the IIF detection of 'AKA'. Moreover, if a commercially marketed kit is developed on the basis of these results, it will be easier to use by clinical laboratories than IIF, because of its limited technical requirements.
This immunoblotting assay should rapidly be confirmed as the most effective method for the serological diagnosis of RA.
